NCT04934475: Phase 3 - IFM 2020-02 Minimal Residual Disease Adapted Strategy (MIDAS) KRD-Isatuximab
NCT04751877: Phase 3 - Isa-Rd +/- Bortezomib Non Frail NTE Myeloma Elderly Patients IFM2020-05
NCT04998786: Phase 2: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide & Dex RRMM
NCT04287855: Phase 2: Phase 2 Study of Isatuximab + Pomalidomide, Dex, Carfilzomib RRMM -IFM2018-03
NCT04144387: IFM2017 Evaluation of the Impact of the Update SMM Criteria on the Natural History SMM
NCT03993912: Phase 3 - Lenalidomide & SC Daratumumab vs Lenalidomide and Dex in NDMM - (IFM2017_03)
NCT03757221: Phase 2 - IFM 2018-02 - Ixazomib -Daratumumab Without Dex in Elderly RRMM (IDARA)
NCT03606577: Phase 2-IFM 2018 - 04 - Quadruplet Induction & Consolidation + Tandem ASCT Hi Risk NDMM
NCT02541383: Phase 3 - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT (CASSIOPEIA)
NCT02197221: Phase 3: Bortezomib-Melphalan Conditioning Regimen vs Melphalan - Frontline Transplant
NCT01971658: Phase 3: Efficacy Study Comparing VTD Versus VCD as Induction NDMM - IFM2013-04
NCT01191060: Phase 3 - IFM 2009 - (IFM/DFCI2009) Conventional dose RVD to High-Dose + ASCT -NDMM
NCT00689936: Phase 3 - Lenalidomide+low dose dex vs Melphalan, Prednisone, Thalidomide in NDMM FIRST
NCT00430365: Phase 3 - IFM2005-02 - Maintenance Therapy Using Lenalidomide in Myeloma
NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma
NCT00200681 : Phase 3- IFM 2005-01: Velcade/Dex Vs Vincristine/Adriamycin/Dex (VAD) for MM
Single versus double autologous stem-cell transplantation for multiple myeloma
IFM 9502 trial: 200 mg/m(2) melphalan Vs 8 Gy TBI + 140 mg/m(2) melphalan as conditioning Blood 2002
IFM trial: Conventional chemo or high-dose therapy and auto bone marrow transplantation - NEJM 1996